Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Multiple Sclerosis
Interventions
DRUG

Nerispirdine

tablet, oral administration

DRUG

placebo

tablet, oral administration

Trial Locations (7)

08807

Sanofi-aventis Administrative Office, Bridgewater

Unknown

Sanofi-aventis Administrative Office, Laval

Sanofi-aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-aventis Administrative Office, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00811902 - Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter